GSK on Monday said it was buying US-based biopharmaceutical company IDRx for up to $1.15bn. IDRx specialises in developing treatments for gastrointestinal stromal tumours (GIST), GSK will pay $1bn up ...
Some results have been hidden because they may be inaccessible to you